Hyperactivity Disorder In Children Research Articles

The association between junk foods consumption and attention deficit hyperactivity disorder in children and adolescents: a systematic review and meta-analysis of observational studies.

The adverse effects of junk foods on the risk of attention deficit hyperactivity disorder(ADHD) symptoms were reported in several studies. In this meta-analysis, the association between junk food consumption and the risk of ADHD was investigated in children and adolescents. A comprehensive systematic search was conducted to find all relevant literature via four databases, including PubMed, Web of Science, Scopus, and Google scholar, up to September 2022. Two independent authors screened all documents based on inclusion criteria. The overall effect sizes and related 95% confidence interval (CI) were pooled with the random effect approach. Subgroup analysis was done to measure potential sources of heterogeneity between studies. The quality of the included studies was evaluated with The Newcastle-Ottawa scale (NOS). Nine observational studies with 58,296 children /adolescents were eligible to be include in the meta-analysis. According to the random effect model, there was a positive relation between the consumption of junk foods and ADHD symptoms (odds ratio (OR): 1.24, 95%CI 1.15-1.34, P < 0.001, I2: 37.4%, P = 0.085). A similar significant positive association was shown in the subgroups analysis by different junk foods (sweetened beverages/soft drinks, sweets/candies, and other types of junk foods). This meta-analysis finding demonstrated that consuming junk foods, especially sweetened beverages/soft drinks, and sweets/candies is associated with ADHD symptoms.

Attention deficit hyperactivity disorder in children with epilepsy: a multicenter cross-sectional analysis in China.

The diagnosis and treatment of attention deficit hyperactivity disorder (ADHD) comorbid with epilepsy have been insufficiently addressed in China. We conducted a study in China to investigate the current status, diagnosis, and treatment of ADHD in children to further our understanding of ADHD comorbid with epilepsy, strengthen its management, and improve patients' quality of life. We carried out a multicenter cross-sectional survey of children with epilepsy across China between March2022 and August2022. We screened all patients for ADHD and compared various demographic and clinical factors between children with and without ADHD, including gender, age, age at epilepsy onset, duration of epilepsy, seizure types, seizure frequency, presence of epileptiform discharges, and treatment status. Our objective was to explore any possible associations between these characteristics and the prevalence of ADHD. Overall, 395 epilepsy patients aged 6-18years were enrolled. The age at seizure onset and duration of epilepsy ranged from 0.1-18 to 0.5-15years, respectively. Focal onset seizures were observed in 212 (53.6%) patients, while 293 (76.3%) patients had epileptiform interictal electroencephalogram (EEG) abnormalities. Among the 370 patients treated with anti-seizure medications, 200 (54.1%) had monotherapy. Although 189 (47.8%) patients had ADHD, only 31 received treatment for it, with the inattentive subtype being the most common. ADHD was more common in children undergoing polytherapy compared to those on monotherapy. Additionally, poor seizure control and the presence of epileptiform interictal EEG abnormalities may be associated with a higher prevalence of ADHD. While the prevalence of ADHD was higher in children with epilepsy than in normal children, the treatment rate was notably low. This highlights the need to give more importance to the diagnosis and treatment of ADHD in children with epilepsy.

Electroencephalogram-Based ConvMixer Architecture for Recognizing Attention Deficit Hyperactivity Disorder in Children.

Attention deficit hyperactivity disorder (ADHD) is a neuro-developmental disorder that affects approximately 5-10% of school-aged children worldwide. Early diagnosis and intervention are essential to improve the quality of life of patients and their families. In this study, we propose ConvMixer-ECA, a novel deep learning architecture that combines ConvMixer with efficient channel attention (ECA) blocks for the accurate diagnosis of ADHD using electroencephalogram (EEG) signals. The model was trained and evaluated using EEG recordings from 60 healthy children and 61 children with ADHD. A series of experiments were conducted to evaluate the performance of the ConvMixer-ECA. The results showed that the ConvMixer-ECA performed well in ADHD recognition with 94.52% accuracy. The incorporation of attentional mechanisms, in particular ECA, improved the performance of ConvMixer; it outperformed other attention-based variants. In addition, ConvMixer-ECA outperformed state-of-the-art deep learning models including EEGNet, CNN, RNN, LSTM, and GRU. t-SNE visualization of the output of this model layer validated the effectiveness of ConvMixer-ECA in capturing the underlying patterns and features that separate ADHD from typically developing individuals through hierarchical feature learning. These outcomes demonstrate the potential of ConvMixer-ECA as a valuable tool to assist clinicians in the early diagnosis and intervention of ADHD in children.

Screen time and effects on attention deficient hyperactivity disorder in children - A systematic review

In recent years, screen time exposure and attention-deficit hyperactivity disorder (ADHD) symptom interrelations in children have garnered increasing attention. Understanding the screen time’s impact on ADHD has become crucial due to its potential influence on socialization, neurobehavioral development, and the prevalence of ADHD among pediatric populations. Conforming to the guidelines of the preferred reporting items for systematic reviews and meta-analyses, a systematic examination was undertaken, centering on research investigating the correlation between screen time and ADHD symptoms in children. The search encompassed databases including MEDLINE (through PubMed), ScienceDirect, Wiley online library, PsycINFO, ERIC, JSTOR, and PsycArticles, utilizing descriptors such as “screen time” and “attention-deficit hyperactivity disorder.” The initial search yielded 2480 articles, supplemented by an additional 10 articles from reference searches, resulting in a total of 2480 records. Excluding the duplicates, 1590 articles were screened based on abstracts, of which 130 underwent full-text examination. Ultimately, 15 studies included in this review met the inclusion criteria. These studies, conducted between 2013 and 2023, comprised cross-sectional, longitudinal, and interventional designs, presenting varying associations between screen time and ADHD symptoms across different age groups. The findings from the selected studies depict a complex relationship between screen time exposure and ADHD symptoms in children. While some studies highlight significant correlations between increased screen exposure and ADHD symptoms, others present conflicting results, indicating the need for further research. Understanding these nuances is crucial in formulating targeted interventions and delineating clearer guidelines to manage screen time concerning ADHD in children.

Attention Deficit Hyperactivity Disorder in Children and Adolescents: Lessons from the COVID-19 Pandemic

Attention Deficit Hyperactivity Disorder in Children and Adolescents: Lessons from the COVID-19 Pandemic

The Prevalence of Attention Deficit Hyperactivity Disorder in Children and Adolescents: An Umbrella Review of Global Evidence

IntroductionFrom recent epidemiological studies to emerging epidemiological evidence, it becomes evident that numerous primary studies have investigated the prevalence of ADHD in children and adolescents. Additionally, several systematic reviews and meta-analyses have explored this subject. The objective of this umbrella review is to offer a robust synthesis of evidence derived from these systematic reviews and meta-analysesObjectivesTo conduct a comprehensive umbrella review that synthesizes emerging epidemiological evidence regarding the prevalence of ADHD in children and adolescents, drawing insights from numerous primary studies as well as systematic reviews and meta-analyses.MethodsWe conducted a systematic search across multiple databases, including PubMed, Web of Science, PsychINFO, and Scopus, to identify relevant studies. The study was preregistered with PROSPERO (registration number: CRD42023389704). To assess the quality of these studies, we utilized the Measurement Tool to Assess Systematic Reviews (AMSTAR). We employed an inverse variance-weighted random-effects meta-analysis to combine prevalence estimates from the included studies.ResultsThe final analysis incorporated thirteen meta-analytic systematic reviews, encompassing 588 primary studies and a total of 3,277,590 participants. A random-effects meta-analysis of these studies revealed that the global prevalence of ADHD in children and adolescents stood at 8.0% (95% CI: 6.0%–10%). Notably, the prevalence estimate was twice as high in boys (10%) compared to girls (5%). Among the three subtypes of ADHD, the inattentive type (ADHD-I) emerged as the most prevalent, followed by the hyperactive type (ADHD-HI) and the combined type (ADHD-C).ConclusionsThe comprehensive umbrella review findings emphasize the high prevalence of ADHD in children and adolescents, with a notable gender disparity, wherein boys are twice as likely to be affected compared to girls. These results underscore the urgency of prioritizing prevention, early identification, and treatment strategies for ADHD in children and adolescents.Disclosure of InterestNone Declared

Синдром дефіциту уваги з гіперактивністю в дітей віком 6-8 років як медико-соціальна проблема

One of the medical and social problems that are considered urgent today is the need to improve the health of children with disorders of mental development, including attention deficit hyperactivity disorder (ADHD). Purpose - to conduct a systematic analysis of scientific sources regarding the etiopathogenesis, clinical manifestations, and joint practical work of doctors, social workers, and teachers regarding ADHD in children 6-8 years old. Domestic and international studies prove that the treatment of ADHD in children should be comprehensive, include recommendations on regime and lifestyle, drug therapy, and practical recommendations from an educational component. A multidisciplinary approach to determine clinical-psychopathological and clinical-psychological regularities of the mental development of children with ADHD is relevant. A feature of such children is high activity, inability to focus on one thing, short-temperedness. But such a condition can be corrected if treatment is started as early as possible. The cause of the development of the disorder can be: complications during pregnancy (this includes early toxicosis, preeclampsia, intrauterine hypoxia of the fetus), complications during childbirth (premature, rapid); low body weight of the child at birth or suffered serious diseases during the first year of life; the presence of bad habits in a pregnant woman, hard work or work in harmful conditions during the period of bearing the fetus. The main signs of attention deficit hyperactivity disorder in children 6-8 years old are as follows: inattention; hyperactivity; impulsiveness. The main symptoms of ADHD can also be accompanied by accompanying symptoms: difficulties in learning, even despite high intellectual abilities; tics; quick fatigue; the presence of phobias, anxiety and depression; autism; sleep problems; speech or behavior disorders. Scientists consider the features of intellectual development of children with ADHD to be voluntary regulation of mental activity, cognitive functions, speech, voluntary motor activity, insufficient development of perceptual-gnostic and emotional spheres. No conflict of interests was declared by the author.

Risk assessment of attention deficit hyperactivity disorder in children with sleep-disordered breathing

Risk assessment of attention deficit hyperactivity disorder in children with sleep-disordered breathing

Prevalence of attention-deficit hyperactivity disorder in children, adolescents and adults in the Middle East and North Africa region: a systematic review and meta-analysis

ObjectivesTo systematically estimate the overall prevalence of attention-deficit hyperactivity disorder (ADHD) in children, adolescents and adults across the Middle East and North Africa (MENA) region.DesignSystematic review and meta-analysis conducted according...

Attention deficit hyperactivity disorder in children and adolescents: lessons from the COVID-19 pandemic

To limit the spread of the coronavirus infection COVID-19, which has received the status of a pandemic, a lockdown was temporarily introduced. In conditions of isolation, children and adolescents suffering from attention deficit hyperactivity disorder (ADHD) were faced with forced changes in their daily routine in the form of a transition to distance learning, a decrease in physical activity, an increase in time in front of TV screens/computer monitors/tablets, etc. The review provides current evidence on the associations between social restrictions caused by the COVID-19 pandemic and behavioral problems in children and adolescents with ADHD. The main factors that can influence the severity of the disease in children and adolescents are analyzed. Particular attention is paid to the role of parental behavior and its influence on the manifestations of ADHD in children in isolation. The results of numerous observations and online surveys of relatives and children suffering from ADHD have demonstrated a multidirectional trajectory of the disease depending on numerous factors, including relationships with parents and immediate family. Despite the end of the COVID-19 pandemic, the effects of isolation during critical periods of childhood have the potential to increase the burden of mental illness. Treatment of children and adolescents with ADHD during the COVID-19 pandemic should be pathogenetic, taking into account the main symptoms of the disease. When choosing pharmacotherapy, priority should be given to drugs with verified effectiveness and a reliable safety profile.

Therapeutic efficacy of probiotics for symptoms of attention-deficit hyperactivity disorder in children and adolescents: meta-analysis.

The efficacy of probiotics as a therapeutic alternative for attention-deficit hyperactivity disorder (ADHD) remain unclear. To investigate the effectiveness of probiotics for symptoms of ADHD and identify possible factors affecting their efficacy. Randomised placebo-controlled trials were identified through searching major databases from inception to April 2023, using the main keywords 'probiotics' and 'ADHD' without limitation on languages or geographic locations. The outcome of interest included improvement in total symptoms of ADHD, symptoms of inattention and hyperactivity/impulsivity, and drop-out rate. Continuous and categorical data were expressed as effect sizes based on standardised mean differences (SMDs) and odds ratios, respectively, with 95% confidence intervals. Meta-analysis of seven trials involving 379 participants (mean age 10.37 years, range 4-18 years) showed no significant improvement in total symptoms of ADHD (SMD = 0.25; P = 0.12), symptoms of inattention (SMD = 0.14; P = 0.3) or hyperactivity/impulsivity (SMD = 0.08; P = 0.54) between the probiotic and placebo groups. Despite non-significance on subgroup analyses, there was a large difference in effect size between studies using probiotics as an adjunct to methylphenidate and those using probiotics as supplementation (SMD = 0.84 v. 0.07; P = 0.16), and a moderate difference in effect size between studies using multiple strains of probiotics and those using single-strain regimens (SMD = 0.45 v. 0.03; P = 0.19). Current evidence shows no significant difference in therapeutic efficacy between probiotics and placebos for treatment of ADHD symptoms. However, albeit statistically non-significant, higher therapeutic efficacies associated with multiple-strain probiotics or combining probiotics with methylphenidate may provide direction for further research.

Novel drug treatments for pain in advanced cancer and serious illness: a focus on neuropathic pain and chemotherapy-induced peripheral neuropathy.

Drugs that are commercially available but have novel mechanisms of action should be explored as analgesics. This review will discuss haloperidol, miragabalin, palmitoylethanolamide (PEA), and clonidine as adjuvant analgesics or analgesics. Haloperidol is a sigma-1 receptor antagonist. Under stress and neuropathic injury, sigma-1 receptors act as a chaperone protein, which downmodulates opioid receptor activities and opens several ion channels. Clinically, there is only low-grade evidence that haloperidol improves pain when combined with morphine, methadone, or tramadol in patients who have cancer, pain from fibrosis, radiation necrosis, or neuropathic pain. Miragabalin is a gabapentinoid approved for the treatment of neuropathic pain in Japan since 2019. In randomized trials, patients with diabetic neuropathy have responded to miragabalin. Its long binding half-life on the calcium channel subunit may provide an advantage over other gabapentinoids. PEA belongs to a group of endogenous bioactive lipids called ALIAmides (autocoid local injury antagonist amides), which have a sense role in modulating numerous biological processes in particular non-neuronal neuroinflammatory responses to neuropathic injury and systemic inflammation. Multiple randomized trials and meta-analyses have demonstrated PEA's effectiveness in reducing pain severity arising from diverse pain phenotypes. Clonidine is an alpha2 adrenoceptor agonist and an imidazoline2 receptor agonist, which is U.S. Federal Drug Administration approved for attention deficit hyperactivity disorder in children, Tourette's syndrome, adjunctive therapy for cancer-related pain, and hypertension. Clonidine activation at alpha2 adrenoceptors causes downstream activation of inhibitory G-proteins (Gi/Go), which inhibits cyclic Adenosine monophosphate (AMP) production and hyperpolarizes neuron membranes, thus reducing allodynia. Intravenous clonidine has been used in terminally ill patients with poorly controlled symptoms, in particular pain and agitation.

Prevalence and risk factors of attention deficit hyperactivity disorder in children admitted to the emergency department due to traumas.

This study aims to determine the prevalence of Attention Deficit Hyperactivity Disorder (ADHD) symptoms and the associated risk factors in children admitted to the Emergency Department (ED) due to traumas. EChildren aged 3-16 years admitted to the ED for traumas were included in the study. The control group consisted of children aged between 3-16, who visited the pediatric ED for non-traumatic reasons. The Revised Conners Parent Rating Scale (CPRS-R) was administered to parents who agreed to participate following initial intervention and stabilization. Trauma patients were divided into two groups: those diagnosed with ADHD and those without ADHD. Risk factors likely to increase the identification of ADHD were assessed. The study included 917 children, with both groups showing similar characteristics regarding age, sex, demographic, and cultural factors. The most common reason for ED visits was extremity traumas, accounting for 296 (35.2%) cases. The majority of trauma patients (95.9%) were discharged from the ED after outpatient interventions. All subscale scores of the CPRS-R, except for the social problems subscale, were significantly higher in the study group compared to the control group. Factors that increased the risk of ADHD included admission with extremity traumas (p<0.001), previous ED admissions due to traumas (p<0.001), and having a family member previously diagnosed with ADHD (p<0.001). The prevalence of ADHD symptoms may be higher in children admitted to the ED due to traumas. Furthermore, extremity traumas, previous trauma-related ED-admissions, and a family history of ADHD increase the risk of ADHD.

Stuttering worsened with atomoxetine treatment in a child with attention deficit and hyperactivity disorder

Stuttering; is defined as a deterioration in the fluency and timing of speech that can occur at any age, and which is inappropriate to the individual’s age and language skills. Several factors play a role in its etiology. Medications are one such factor. Atomoxetine is a drug that is frequently employed and well- tolerated in the treatment of attention-deficit hyperactivity disorder in children and adolescents. Stuttering is not a common side- effect when using atomoxetine. This report describes, a seven-year-old patient whose stuttering worsened significantly during atomoxetine use. This case is reported due to the scarcity of cases in which stuttering worsened during the use of atomoxetine.

BAZI TIBBİ BİTKİLERDE ATOMOKSETİN TAYİNİ İÇİN YENİ BİR UHPLC-DAD YÖNTEMİNİN GELİŞTİRİLMESİ VE VALİDASYONU

Objective: Atomoxetine (ATX) is a medication that is extensively used to treat attention deficit hyperactivity disorder in children, adolescents, and adults. The goal of this work was to create a speedy, easy, and sensitive ultra high performance liquid chromatographic method (UHPLC) for the measurement of atomoxetine in various medicinal plants. (Salvia officinalis L., Rosmarinus officinalis L., Melissa officinalis L., Ginkgo biloba L.). Material and Method: Prior to chromatographic separation, liquid-liquid extraction was applied, which is currently the preferred extraction technique due to its simple, fast and efficient procedure for sample preparation. The chromatographic separation was achieved by reversed phase C18 (5 μm × 4.6 mm × 150 mm) analytical column and a mobile phase consisting of monobasic potassium dihydrogen orthophosphate (pH=6.8) and acetonitrile (50:50 v/v) at flow rate of 0.8 ml/min and diode array detector (DAD) detecting at 215±2 nm. Result and Discussion: The envisioned method's linear behavior was tested in the 0.5-20 μg/ml range (r2=0.09990). In compliance with International Conference on Harmonisation (ICH) criteria, the method received validation by means of accuracy, precision, repeatability, specificity, robustness, and detection and quantification boundaries. LOD and LOQ values were determined as 0.16 and 0.5 μg/ml. RSD values for hourly and daily measurements are found to be below 2.5% for both assays. The proposed method can be used effectively for quantification of atomoxetine in medicinal and aromatic plants. The proposed analytical procedure represents an efficient method for the quantification and routinee analysis of atomoxetine in medicinal and aromatic plants.

Efficacy of behavior modification training combined with electroencephalographic biofeedback therapy for attention deficit hyperactivity disorder in children: a randomized controlled trial

Efficacy of behavior modification training combined with electroencephalographic biofeedback therapy for attention deficit hyperactivity disorder in children: a randomized controlled trial

Assessment of probiotic strain Lactobacillus acidophilus LB supplementation as adjunctive management of attention-deficit hyperactivity disorder in children and adolescents: a randomized controlled clinical trial

BackgroundThis study was designed to examine the possible efficacy of the probiotic strain Lactobacillus acidophilus LB (Lacteol Fort) on attention-deficit/hyperactivity disorder (ADHD) symptomatology and evaluate its influence on cognition function.MethodsIn this randomized controlled trial, 80 children and adolescents with ADHD diagnosis, aged 6–16 years, were included. The participants were randomly assigned to two groups: one group received probiotics plus atomoxetine, whereas the other group received atomoxetine only. ADHD symptomatology was assessed using the Conners Parent Rating Scale–Revised Long Version (CPRS-R-L) and Child Behavioral Checklist (CBCL/6–18). The participants were evaluated for their vigilance and executive function using Conner’s Continuous Performance Test (CPT) and Wisconsin Card Sort Test (WCST). Both groups were assessed at the beginning of the study and the end of the twelve weeks.ResultsThe probiotic group comprised 36 patients, whereas the control group comprised 40 patients in the final analysis after four patients dropped out of the trial. After 3 months of probiotic supplementation, a significant improvement in the CPRS-R-L and CBCL total T scores was observed compared with those in the control group (p = 0.032, 0.024, respectively). Additionally, the probiotic group demonstrated improved focus attention (target accuracy rate and omission errors;p = 0.02, 0.043, respectively) compared with the control group. An analysis of the Wisconsin Card Sorting Test (WCST) performance demonstrated that the probiotic group had significantly lower perseverative (p = 0.017) and non-perseverative errors (p = 0.044) but no significant differences compared to the control group.ConclusionLactobacillus acidophilus LB supplementation combined with atomoxetine for 3 months had a beneficial impact on ADHD symptomology and a favorable influence on cognitive performance. As a result, the efficacy of probiotics as an adjunctive treatment for managing ADHD may be promising.Trial registrationClinicalTrials.gov (identifier: NCT04167995). Registration date: 19–11-2019.

Recent advances in the treatment of attention deficit hyperactivity disorder in children: A narrative review

Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder characterized by age inappropriate levels of inattention, and or impulsivity and hyperactivity. Often arising in childhood, ADHD can also be chronic in nature, frequently continuing through adolescence and beyond, at least at the level of impairment. The early accurate diagnosis of the condition is possible based on clinic settings, clinicians’ expertise; and the context at which screening and evaluation of this population for ADHD is done. ADHD is an etiologically complex neurodevelopmental disorder that begins early in life and has heterogeneous clinical manifestations encompassing a broader spectrum of psychopathology. This underscores the importance of early accurate diagnosis so that effective treatments can be started that significantly reduces immediate and long-term psychosocial burdens. Effective ADHDtreatments are available and cognitive neuroscience is rapidly expanding, however there is a significant gap between empirical evidence and clinical practice. Multimodal and multidisciplinary treatment strategies are the best approach in the treatment, but there is a significant gap between the knowledge and practice, such that evidence-based treatments are often not implemented in the community settings. How we implement such in our clinical practice helps us to advocate and advance towards more effective ADHD treatments. There is growing scientific progress in understanding the causes and treatment of ADHD. Knowledge about the evidence-based recent advances in the treatment helps mental health professionals to advocate for the effective approaches to treat ADHD, with minimal unwanted side effects.

Attention-deficit hyperactivity disorder in children is related to maternal screen time during early childhood in Taiwan: a national prospective cohort study

BackgroundIt is unclear to familial screen time in early childhood is associated with the subsequent diagnosis of attention-deficit and hyperactivity disorder (ADHD). Our study is to evaluate the association between screen time during early childhood in families and the incidence of ADHD.MethodsWe conducted a population-based birth cohort study by using the Taiwan Birth Cohort Study, which recruited 24 200 mother–child pairs when children were 6 months old. Screen time exposure for children and parents were collected at the age of 18 and 36 months. Whether the child has ever been diagnosed with ADHD was determined at a follow-up interview at age 8. Factors including socioeconomic factors and screen time were analyzed using logistic regression to determine their association with the rate of ADHD.ResultsA total of 16 651 term singletons were included in the final analysis. Of them, 382 (2.3%) were diagnosed as having ADHD before the age of 8 years. No significant relationship between children’s or fathers’ screen time and ADHD was noted. When compared to children whose mothers spent less time on screens, those whose mothers spent more than 3 h a day on screens when the child was 3 years old exhibited a higher incidence of ADHD (adjusted OR [aOR]: 1.31, 95% CI: 1.03–1.66).ConclusionHigher maternal screen time when the child was 3 years old was associated with an increased incidence of ADHD in this population-based study. However, children’s screen time did not find related to ADHD. We found that it was the mother’s screen time, who typically serves as the primary caregiver in our study participants, not the child’s, that mattered. In addition to superficial screen use time, future research is needed to replicate the findings and clarify mechanisms underlying this association.

The therapeutic effect of ceramic art-assisted drug therapy on hyperactivity disorder in children

BackgroundHyperactivity disorder in children is a common neurodevelopmental disorder that seriously affects children’s learning and quality of life. Therefore, it is clinically important to find new treatment methods.Subjects and Methods The study selected 100 cases of pediatric patients in a hospital between March 2021 and January 2022. They were randomly divided into an observation group and a control group, with 50 cases in each group. The observation group received ceramic art-assisted drug therapy, and the control group received conventional drug therapy. By observing and recording the anxiety scores, attention scores, and behavioral problems scores of the study subjects during the treatment process, while using SPSS22.0 software for data analysis, the differences in the treatment effects of the two groups were compared and tested for significance.ResultsThe mean values of anxiety scores decreased by 30.26% and 15.49%, the mean values of attention scores increased by 20.26% and 11.54%, and the mean values of behavioural problem scores decreased by 24.06% and 18.83% in the observation group and the control group, respectively, after treatment. The observation group was better than the control group in anxiety scores, attention scores and behavioural problem scores, and the differences were all statistically significant (P&lt;0.05).ConclusionsCompared with conventional medication, ceramic art-assisted medication can significantly reduce anxiety scores, improve attention scores and reduce behavioural problems, which has clinical promotion and application value.